Pentoxifylline affects cytokine reaction in cardiopulmonary bypass

Heart Surg Forum. 2006;9(6):E883-7. doi: 10.1532/HSF98.20061090.


Background: Cardiac surgery is associated with an inflammatory response that may cause myocardial dysfunction after cardiopulmonary bypass. We examined the efficacy of pentoxifylline to attenuate the cardiopulmonary bypass-induced inflammatory response during heart operations.

Methods: In a prospective, randomized study, 30 patients undergoing coronary artery bypass graft surgery received either pentoxifylline (group P, n = 15) (continuous infusion of 1.5 mg/kg per hour during operation) or not (group C [control], n = 15). Blood samples for measurements of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and IL-10 were taken from the arterial line in both groups at 5 different time points.

Results: TNF-alpha, IL-6, and IL-8 plasma levels increased in both groups after cardiopulmonary bypass, with a higher increase in the control group (P < .05).

Conclusions: Our results indicate that pentoxifylline infusion during cardiac surgery inhibits the proinflammatory cytokine release caused by cardiopulmonary bypass.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiopulmonary Bypass / adverse effects*
  • Cytokines / blood*
  • Female
  • Humans
  • In Vitro Techniques
  • Male
  • Middle Aged
  • Myositis / etiology
  • Myositis / immunology*
  • Myositis / prevention & control*
  • Pentoxifylline / administration & dosage*
  • Platelet Aggregation Inhibitors / administration & dosage
  • Treatment Outcome


  • Cytokines
  • Platelet Aggregation Inhibitors
  • Pentoxifylline